[{"indications": "Indications\u00a0short-term treatment of symptoms of oestrogen deficiency (including\r\nwomen being treated with gonadotrophin releasing hormone analogues);\r\nosteoporosis prophylaxis in women at risk of fractures (second-line)", "name": "TIBOLONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.1 Oestrogens and HRT", "TIBOLONE"], "cautions": "Cautions\u00a0see Hormone Replacement Therapy and under Oestrogens for HRT; vaginal bleeding\r\n(investigate for endometrial cancer if bleeding continues beyond 6\r\nmonths or after stopping treatment); history\r\nof liver disease, epilepsy, migraine, diabetes mellitus, hypercholesterolaemia; withdraw if signs of thromboembolic disease, abnormal\r\nliver function tests or cholestatic jaundice; see also Note below; interactions: Appendix 1\r\n(tibolone)", "side-effects": "Side-effects\u00a0see notes above; also abdominal pain, weight changes,\r\nvaginal bleeding, leucorrhoea, facial hair, and rarely amnesia; gastro-intestinal disturbances, oedema, dizziness, headache,\r\nmigraine, depression, breast cancer (see notes above and %s\n(From Hormone replacement therapy: British National Formulary)\nHormone replacement therapy), arthralgia, myalgia, visual\r\ndisturbances, seborrhoeic dermatitis, rash and pruritus also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4331.htm", "doses": ["2.5\u00a0mg daily", "Unsuitable for use in the premenopause (unless\r\nbeing treated with gonadotrophin-releasing hormone analogue) and as\r\n(or with) an oral contraceptive; also unsuitable for use within 12\r\nmonths of last menstrual period (may cause irregular bleeding); induce\r\nwithdrawal bleed with progestogen if transferring from another form\r\nof HRT"], "pregnancy": "Pregnancy\u00a0avoid; toxicity in animal studies"}]